Ranibizumab

Description

Ranibizumab is used to treat certain types of eye disorders. It is used for the treatment of a wet type of age-related macular degeneration, an eye disease that impairs central vision. It is also used for the treatment of swelling in the retina resulting due to diabetes or by blockage of blood flow from the eye.

Side effects

Major & minor side effects for Ranibizumab

  • Blindness
  • Blurred vision
  • Dizziness
  • Eye pain
  • Irregular heartbeat
  • Unexplained weight loss
  • Back pain

Uses of Ranibizumab

What is it prescribed for?

  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Diabetic retinopathy
  • Macular Edema
  • Diabetic macular edema
Read More
Concerns

Commonly asked questions

  • Onset of action
    The amount of time required for this medicine to show its action is not clinically established.
  • Duration of effect
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Safe with alcohol?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?
    No habit-forming tendencies were reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.

Allergy

This medicine is not recommended for use if you have a known allergy to Ranibizumab or any other inactive ingredient present along with it.

Ocular infection or Periocular infections

This medicine is not recommended for use in patients with infectious eye diseases due to the increased risk of worsening of the patient's condition.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.
General warnings

Thromboembolic events

This medicine may cause serious arterial thromboembolic events in some patients. Appropriate corrective measures, dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Increase in intraocular pressure

This medicine may increase the intraocular pressure and hence should be used with extreme caution in patients with glaucoma (increased intraocular pressure) due to the increased risk of worsening of the patient's condition. It is recommended to monitor the intraocular pressure before and after therapy with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Visual disturbances

This medicine may cause temporary visual disturbances in some patients on therapy. It is advised that you do not perform any activities that require high mental alertness like driving a vehicle or operating machinery if you experience any such symptoms.

Use in children

This medicine is not recommended for use in patients below 18 years of age since the safety and efficacy of use are not clinically established.

Missed Dose

Since this medicine is usually administered by a qualified healthcare professional in the clinical/hospital setting, the likelihood of a missed dose is very low. However, it is advised to contact the doctor immediately if you miss a scheduled dose of this medicine.

Overdose

Since this medicine is administered in the hospital setting by a qualified healthcare professional, the likelihood of an overdose is very less. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Verteporfin

Disease interactions

Glaucoma

This medicine should be used with extreme caution in patients with glaucoma (increased intraocular pressure) due to the increased risk of worsening of the patient's condition. It is recommended to monitor the intraocular pressure before and after therapy with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.
Food interactions
Information not available.
Lab interactions
Information not available.
This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor. Inform the doctor if you have a known allergy to this medicine. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine.
Miscelleneous

Usage does not depend on food timings

To be taken as instructed by doctor

Effect on sleep is not established

How it works
This medicine works by inhibiting the abnormal blood vessel formation and leakage within the eyes to prevent vision loss.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Anti-angiogenic ophthalmic agents

Schedule

Schedule H

Lucentis 10 mg/ml solution for injection - Summary of Product Characteristics (SmPC) - (eMC) [Internet]. Medicines.org.uk. 2018 [cited 26 December 2018]. Available from:

https://www.medicines.org.uk/emc/product/307/smpc#CLINICAL_PRECAUTIONS

Ranibizumab - DrugBank [Internet]. Drugbank.ca. 2018 [cited 26 December 2018]. Available from:

https://www.drugbank.ca/drugs/DB01270

[Internet]. Accessdata.fda.gov. 2018 [cited 26 December 2018]. Available from:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125156s111lbl.pdf

DailyMed - Lucentis- ranibizumab injection, solution [Internet]. Dailymed.nlm.nih.gov. 2018 [cited 26 December 2018]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d

How will this medicine affect me?

Consult top doctors online and get an answer now
Chat now
Chat now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now
Book now
Something doesn’t feel right?
Report an error

Information on this page was last updated on 30 May 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.